A Phase 1 interventional study of Acalabrutinib in combination with BR and Acalabrutinib in combination with VR in Mantle Cell Lymphoma (MCL), sponsored by Acerta Pharma BV. Active, not recruiting at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell — 5 open to participants now, 20 under way, 1 of them phase 3. acalabrutinib · Lymphoma, Mantle-Cell.
Among the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 1, reaches primary completion later than 1 of the 19 other live ones, and was the 3rd registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →5 of the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Emory University · Sites in United States
Ages 18+
Austin I Kim · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 2 · Phase 4 1
First in 2015; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 49 across the 26 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
15 studies in Lymphoma, Mantle-Cell by AstraZeneca: 3 open now, 8 under way, 1 of them phase 3. Of 6 finished, 3 (50%) have results posted.
Among the 15 studies in Lymphoma, Mantle-Cell by AstraZeneca, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2016, is one of 3 in phase 1, and was the 4th registered.
AstraZeneca’s Lymphoma, Mantle-Cell studies by the year they started, since 2005.
7 of the studies testing acalabrutinib in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02972840Phase 3Acerta Pharma BVA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | 2027-02-15 |
| NCT04115631ECOG-ACRIN Cancer Research GroupA Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | 2026-12-31 |
| NCT04484012City of Hope Medical CenterModified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | 2027-02-23 |
| NCT05495464M.D. Anderson Cancer CenterA Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | 2027-03-31 |
| NCT04189757M.D. Anderson Cancer CenterAcalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, from their registry updates:
Among AstraZeneca’s 15 in Lymphoma, Mantle-Cell:
This tab as a report to print or save as PDF → With an account.
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma
This is a multicenter, open-label Phase 1b study to assess the safety and efficacy of acalabrutinib when administered concomitantly with bendamustine and rituximab in subjects with treatment naive or relapse refractory mantle cell lymphoma (Part 1), or when administered concomitantly with venetoclax and rituximab in subjects with treatment naive mantle cell lymphoma (Part 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Acalabrutinib in combination with drugs bendamustine and rituximab (BR) in treatment naive patients
Drug: Acalabrutinib in combination with BR
Part 1: Acalabrutinib in combination with bendamustine and rituximab (BR) in relapse refractory patients
Drug: Acalabrutinib in combination with BR
Part 2: Acalabrutinib in combination with venetoclax and rituximab (VR) in treatment naive patients
Drug: Acalabrutinib in combination with VR
Drug page: Acalabrutinib
Also known as: Acalabrutinib + BR
Drug page: Acalabrutinib
Also known as: Acalabrutinib + VR
Number of Participants with Treatment Emergent Adverse Events (AEs) as assessed by CTCAE v4.03
Number of participants who had experienced at least one treatment emergent AE
Time frame: From first dose of study drug to within 30 days of last dose of study drug
Ran from Apr 2016 to primary completion in Jun 2022, 73 months.
Of 55 industry-sponsored phase 1 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's 73 months is above that.
Counting every sponsor, half of 128 studies reached it within 61 months; a quarter within 36 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib